Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse [0.03%]
Panagiotis Tsirigotis,Maria Garofalaki,Ioanna Lazana et al.
Panagiotis Tsirigotis et al.
The prognostic value of NPM1-mut Measurable Residual Disease (MRD) has been increasingly recognized. However, real-world data validating the prognostic impact of NPM1-mut MRD remains limited. The aim of this study was to assess the prognost...
A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma [0.03%]
Gabriele Gugliotta,Lisa Argnani,Martina Cantelli et al.
Gabriele Gugliotta et al.
The use of immune checkpoint inhibitors (ICIs) has deeply improved the outcome of relapsed or refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL) patients. However, real-world data are still limited, and several aspects, including ...
Combination of Ocular Radiation With Systemic Chemotherapy for Treatment of Primary Vitreoretinal Lymphoma: A Prospective Single Center Cohort With Long Follow-Up [0.03%]
Asaad Trabolsi,Jennifer Keenan,Derek Isrow et al.
Asaad Trabolsi et al.
Robert T Means Jr
Robert T Means Jr
Jules Mercier-Ross,Zhixin Yang,Alexis Zebrowski et al.
Jules Mercier-Ross et al.
Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-Up [0.03%]
Jennifer A Woyach,Relja Popovic,Emily L Rossi et al.
Jennifer A Woyach et al.
Second Allogeneic Hematopoietic Cell Transplantation After Graft Failure Is an Effective Curative Option in Children With Hemoglobinopathies [0.03%]
Arianna Panigari,Mattia Algeri,Pietro Merli et al.
Arianna Panigari et al.
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial [0.03%]
Nichola Cooper,Catherine M Broome,Yoshitaka Miyakawa et al.
Nichola Cooper et al.
Primary autoimmune thrombocytopenia (ITP) is characterized by thrombocytopenia, bleeding, and reduced health-related quality of life. In the Phase 3 ADVANCE IV study, intravenous efgartigimod induced significant platelet count responses ver...
Lenalidomide-Dexamethasone as an Effective and Well-Tolerated Treatment Option for Refractory Rosai-Dorfman-Destombes Disease: A Clinical and Pharmacophenomic Study [0.03%]
Emily Leung,Nicholas R Fragola,Elliott W Sharp et al.
Emily Leung et al.
A combined clinical and computational pharmacophenomic study from the Coastal Rare Inflammatory Diseases Program and Every Cure. ...